Daniel Loeb’s Ars Pharmaceuticals Inc (SPRY) position
Reported position history, portfolio importance and verified filing changes from public SEC disclosures.
At a glance
The full verified relationship, including prior ownership episodes and exits where supported.
Third Point LLC first reported Ars Pharmaceuticals Inc in Q4 2025. The reported position was increased across later filings. Third Point LLC currently reports 1.00M shares. The latest verified filing showed: No change.
Position over time
See the same verified relationship through reported shares, portfolio weight or reported value.
Gaps indicate periods that cannot be safely connected or where a verified corporate action changes the raw share scale. Stock price, when available, is market context and not a transaction price.
What changed
Latest filing plus the most meaningful reported changes. Unchanged quarters are collapsed by default.
Filing context
Quarter-end price $8.01 · Estimated holding basis $10.04
Filing context
Quarter-end price $8.03 · Estimated holding basis $10.04
Filing context
Quarter-end price $11.65 · Estimated holding basis $11.65
How important is Ars Pharmaceuticals Inc in Third Point LLC’s reported portfolio?
Relative importance is measured only within the verified primary non-option reported portfolio for each quarter.
SEC filing evidence
Market context and filing-derived values are kept separate from actual transaction prices, which 13F filings do not disclose.
Market context only; not an investor transaction price.
Derived from validated reported value and shares where supported.
Calculated from supported filing history.
This tracker follows Third Point LLC’s Form 13F disclosures, not Daniel Loeb’s personal brokerage account. Form 13F reports quarter-end positions later and does not reveal exact trade dates or execution prices.